Results 81 to 90 of about 49,590 (251)

Application of Recombinant VII Activated Coagulation Factor for Children with Resistant Coagulopathy Caused Sepsis

open access: yesМедицинский вестник Юга России, 2010
Purpose: To investigate the effectiveness of recombinant VII activated coagulation factor in complex therapy of children with resistant coagulopathy caused by sepsis. Materials and Methods: 38 children from 2 months to 17 years old were investigated with
N. Bgane, A. Trembach
doaj  

Should APTT become part of thrombophilia screening?

open access: yes
This first and perhaps most important aspect is that the occasional finding of a prolonged APTT, especially in hospitalized patients, cannot necessarily be attributed to preanalytical problems, whereas APTT values may instead reflect a real ex vivo ...
Favaloro, Emmanuel J, Lippi, Giuseppe
core   +1 more source

TP, APTT and fibrinogen reference values in healthy beagle breed dogs [PDF]

open access: yes, 2020
Background: Hemostasis is a process of blood coagulation with the function of preventing hemorrhagic processes in the organism. The Coagulation Time (CT), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, Thrombin Time (TT),
Brito, Helena Cristina Delgado   +3 more
core  

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

open access: yesHaemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini   +4 more
wiley   +1 more source

Development of a Lupus Anticoagulant sensitive APTT Reagent with low heparin and high factor deficiency sensitivity

open access: yes
Activated Partial Thromboplastin Time (APTT) is a widely used assay to assess deficiencies in blood coagulation factors within the intrinsic pathway of coagulation. Nordic Biomarker produces and sells different products and one of them is an APTT reagent
Mathilda, Dahlén
core   +3 more sources

Boxplots of the four aPTT methods’ results for enoxaparin and tinzaparin in three different concentrations.

open access: yes, 2015
When comparing the contiguous groups with the same aPTT-method but different concentrations of LMWH, a significant difference in aPTT was found in all cases. Statistical significances between classes are shown in S1 File.
Owain Thomas (597280)   +4 more
core   +1 more source

Age-associated developmental changes in the activated partial thromboplastin time (APTT) and causes of prolonged APTT values in healthy Chinese children [PDF]

open access: yes, 2009
Background: The concept of developmental hemostasis has been universally accepted. Physiological reference ranges for coagulation tests are available for infants and children of different ages. However, on Oriental children they are rare.
Zhou, Yu   +15 more
core   +2 more sources

Italian Patients Journey for Gene Therapy in Haemophilia A

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno   +19 more
wiley   +1 more source

From Bleeding Control to Health: Implementing Multidimensional and Multidisciplinary Hemophilia Care Into the Era of Therapeutic Innovation

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Over the past decade, hemophilia management has been transformed by modern prophylactic strategies, achieving dramatic reductions in annualized bleeding rates (ABR), often approaching zero. However, the conceptual evolution of hemophilia care toward multidimensional health assessment and comprehensive multidisciplinary management ...
Nicolas Giraud, Yesim Dargaud
wiley   +1 more source

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults

open access: yesDrug Design, Development and Therapy
Zhu Luo,1 Jie Wang,2 Zhuolu Niu,3 Cuili Hu,4 Madhu Chintala,5 Xinchao Luo,3 Tsung-I Lee,3 Alexei N Plotnikov,5 Peter Zannikos5 1Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Department of Hematology,
Luo Z   +8 more
doaj  

Home - About - Disclaimer - Privacy